Valganciclovir: Therapeutic role in pediatric solid organ transplant recipients

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 6, 2013, Pages 807-815

  Yu, Marie A ^a   Park, Jeong M ^b  

^a SHARP GROSSMONT HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Pediatrics; Solid organ transplantation; Valganciclovir

Indexed keywords

BENZIMIDAVIR; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; LEFLUNOMIDE; LETERMOVIR; VALGANCICLOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; CYTOPENIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS INFECTION; FEVER; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; NAUSEA; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PEDIATRIC SURGERY; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; SOLID ORGAN TRANSPLANTATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS REPLICATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CHILD; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; PRODRUGS;

EID: 84875149883     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.778244     Document Type: Article

References (66)

1. Nassetta L, Kimberlin D, Whitley R. Treatment of congenital cytomegalovirus infection: Implications for future therapeutic strategies. J Antimicrob Chemother 2009;63:862-7
2. Nett PC, Heisey DM, Fernandez LA, et al. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004;78:1036-41
3. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004;66:329-37
4. Evans PC, Soin A, Wreghitt TG, et al. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000;69:30-5
5. Asberg A, Rollag H, Hartmann A. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. Expert Opin Pharmacother 2010;11:1159-66
6. Camacho-Gonzalez AF, Gutman J, Hymes LC, et al. 24 weeks of valganciclovir prophylaxis in children after renal transplantation: A 4-year experience. Transplantation 2011;91:245-50
7. Balfour HH Jr, Chace BA, Stapleton JT, et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381-7
8. Flechner SM, Avery RK, Fisher R, et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998;66:1682-8
9. Bock GH, Sullivan EK, Miller D, et al. Cytomegalovirus infections following renal transplantation-effects on antiviral prophylaxis: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997;11:665-71
10. Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008;8:69-77
11. Martin JM, Danziger-Isakov LA. Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation. Pediatr Transplant 2011;15:229-36
12. Saitoh A, Sakamoto S, Fukuda A, et al. A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation. Transplantation 2011;92:930-5
13. Renoult E, Clermont MJ, Phan V, et al. Prevention of CMV disease in pediatric kidney transplant recipients: Evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients. Pediatr Transplant 2008;12:420-5
14. Madan RP, Campbell AL, Shust GF, et al. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients. Transplantation 2009;87:1318-24
15. Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, double-blind, multicenter controlled trial. Am J Transplant 2012;12:3021-30
16. ViroPharma. ViroPharma announces initiation of clinical studies to evaluate maribavir for treatment of cytomegalovirus infection. Available from: Http://ir.viropharma.com/releasedetail.cfm?releaseid=679480 [Accessed 3 February 2013]
17. Available from: Http://clinicaltrials.gov NCT00942305 [Accessed 5 January 2013]
18. Available from: Http://clinicaltrials.gov NCT01063829 [Accessed 5 January 2013]
19. Available from: Http://clinicaltrials.gov NCT00125502 [Accessed 5 January 2013]
20. Available from: Http://clinicaltrials.gov NCT00435396 [Accessed 5 January 2013]
21. Available from: Http://clinicaltrials.gov NCT00285259 [Accessed 5 January 2013]
22. Available from: Http://clinicaltrials.gov NCT00674648 [Accessed 5 January 2013]
23. Available from: Http://clinicaltrials.gov NCT00353977 [Accessed 5 January 2013]
24. Available from: Http://clinicaltrials.gov NCT00373412 [Accessed 5 January 2013]
25. Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005;5:218-27
26. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S78-86
27. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-95
28. Andrews PA, Emery VC, Newstead C. Summary of the British transplantation society guidelines for the prevention and management of CMV disease after solid organ transplantation. Transplantation 2011;92:1181-7
29. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-20
30. Valganciclovir (Valcyte). Genentech USA, Inc, South San Francisco, CA; 2010
31. Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008;197:836-45
32. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005;79:1477-83
33. Scott JC, Partovi N, Ensom MH. Ganciclovir in solid organ transplant recipients: Is there a role for clinical pharmacokinetic monitoring? Ther Drug Monit 2004;26:68-77
34. Fishman JA, Doran MT, Volpicelli SA, et al. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2000;69:389-94
35. Autmizguine J, Theoret Y, Launay E, et al. Low systemic ganciclovir exposure and preemptive treatment failure of cytomegalovirus reactivation in a transplanted child. J Popul Ther Clin Pharmacol 2011;18:e257-60
36. Piketty C, Bardin C, Gilquin J, et al. Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. J Infect Dis 1996;174:188-90
37. Vethamuthu J, Feber J, Chretien A, et al. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant 2007;11:301-5
38. Luck S, Lovering A, Griffiths P, et al. Ganciclovir treatment in children: Evidence of subtherapeutic levels. Int J Antimicrob Agents 2011;37:445-8
39. Freeman RB. Valganciclovir: Oral prevention and treatment of cytomegalovirus in the immunocompromised host. Expert Opin Pharmacother 2004;5:2007-16
40. Pescovitz MD, Ettenger RB, Strife CF, et al. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis 2010;12:195-203
41. Pescovitz MD, Jain A, Robson R, et al. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant Proc 2007;39:3111-16
42. Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009;9:636-43
43. Chawla JS, Ghobadi A, Mosley J III, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: A pilot trial (04-0274) and review of the literature. Transpl Infect Dis 2012;14:259-67
44. Ruiz-Camps I, Len O, de la Camara R, et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. Antivir Ther 2011;16:951-7
45. Clark BS, Chang IF, Karpen SJ, et al. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 2004;77:1480
46. Lapidus-Krol E, Shapiro R, Amir J, et al. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation. Pediatr Transplant 2010;14:753-60
47. Bedel AN, Hemmelgarn TS, Kohli R. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: Comparison of prophylactic oral ganciclovir and oral valganciclovir. Liver Transpl 2012;18:347-54
48. Available from: Http://clinicaltrials.gov NCT01376804 [Accessed 5 January 2013]
49. Available from: Http://clinicaltrials.gov NCT01165580 [Accessed 5 January 2013]
50. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7:2106-13
51. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. J Pediatr 2003;143:16-25
52. Galli L, Novelli A, Chiappini E, et al. Valganciclovir for congenital CMV infection: A pilot study on plasma concentration in newborns and infants. Pediatr Infect Dis J 2007;26:451-3
53. Lombardi G, Garofoli F, Villani P, et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009;28:1465-70
54. Amir J, Wolf DG, Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr 2010;169:1061-7
55. Hocker B, Bohm S, Fickenscher H, et al. (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int 2012;25:723-31
56. Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5:2894-900
57. Turgeon N, Hovingh GK, Fishman JA, et al. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Transpl Infect Dis 2000;2:15-21
58. Keles M, Yildirim R, Uyanik A, et al. Neutropenia related to valacyclovir and valganciclovir in 2 renal transplant patients and treatment with granulocyte colony stimulating factor: A case report. Exp Clin Transplant 2010;8:181-3
59. Jabs DA, Bolton SG, Dunn JP, et al. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998;126:817-22
60. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999;12:286-97
61. Boivin G, Goyette N, Gilbert C, et al. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005;7:166-70
62. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: A French cohort study. J Antimicrob Chemother 2011;65:2628-40
63. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010;90:419-26
64. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008;46:840-6
65. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med 2010;152:761-9
66. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10:1228-37